Potential Research Participants
  • For more information about a specific study, please call the contact person listed for that study.
  • For general questions about participating in research studies at OHSU you may contact the Clinical Research Navigator at (503) 346-3540.
  • If you have any questions regarding your rights as a research subject, you may contact the OHSU Research Integrity Office at (503) 494-7887.

 
Return to Search

 
Study Opportunities (377 Results)
 
1) A Phase II Study of Patients with Newly Diagnosed Primary Central Nervous System Lymphoma Treated with Methotrexate/BBBD, and Adding Rituximab (an anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen
2) Neurocognition and Brain Development in Youth (Attention Deficit)
3) Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction with Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects with Anaplastic Oligodendroglioma or Oligoastrocytoma
4) Oregon Colorectal Cancer Registry
5) MRI Protocol Development and Optimization
6) Oregon Pancreas Tissue Registry
7) Quantitative Dynamic Contrast-Enhanced Breast MRI
8) [UMiami – MOU] TrialNet Natural History Study of the Development of Type 1 Diabetes
9) Phase I/II Study of Intra-arterial Melphalan Given with Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
10) Preclinical studies on endometrial xenografts
11) Oregon Liver Tumor Registry
12) Transepithelial Potential Difference Measurements in Patients with Unusual Variants of Cystic Fibrosis
13) VAPORHCS/OHSU J:Optimization of Cochlear Implants and Hearing Aids
14) I-SPY 2 TRIAL: Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
15) Harold Schnitzer Diabetes Health Center Research Department Contact and Health Information Repository
16) Objective grading of intraocular inflammation in uveitis using optical coherence tomography
17) Relationship between HLA B27, disease status and the human microbiome
18) Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
19) Disorders of Water and Electrolyte Balance
20) Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) Acute Myeloid Leukemia (AML).
21) Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
22) A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
23) Oregon Index of Endocrine Neoplasias (ORION)
24) The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer
25) Longitudinal observational study using functional and structural optical coherence tomography to diagnose and guide treatment of glaucoma
26) A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
27) A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
28) S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
29) VAPORHCS/OHSU J: Identifying the Determinants of Long-Term Type Specific Immunity in a Dengue Immune Cohort
30) CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia (CASCADE FH Registry)
31) A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 Monoclonal Antibody (Relatlimab, BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab BMS-936558) in Relapsed or Refractory B-Cell Malignancies
32) The immunogenicity and safety of Zostavax® and Shingrix® in rheumatoid arthritis patients using abatacept
33) SARC024: A blanket protocol to study oral regorafenib in patients with selected sarcoma subtypes
34) Optical coherence tomography angiography in neovascular age-related macular degeneration
35) A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
36) War on Melanoma: Enlisting a cohort of melanoma survivors and their families
37) Immune Dysregulation in HIV-Infected Adults with Substance Abuse and the Impact of Addiction
38) A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed after First-Line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
39) OCTRI Research Volunteer Registry
40) Urinary Microbiomes: Do they play a role in Urgency Urinary Incontinence?
41) [NCI CIRB]S1400: Lung-MAP, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
42) A Phase II Multicenter Randomized Trial Evaluating 3-Year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management
43) Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
44) Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide (MDV3100) in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
45) A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies
46) Developing A Smart Predictor App for AAC Conversation
47) Developing a National Registry for JORRP (Juvenile Onset Recurrent Respiratory Papillomatosis)
48) Alzheimer's Comprehensive Treatment Network of Oregon and Washington (ACTNOW)
49) Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
50) A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
51) A Phase III, Open-Label Randomized Study of Atezolizumab (Anti-PD-LI Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
52) Sarcoma Survivorship Registry
53) Melanoma Tissue Bank Consortium: A Multi-Center Repository of Biospecimens and Data for Future Use
54) A Phase 1B Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with Other Targeted Anti-cancer Therapies in Subjects with B-cell Malignancies
55) VAPORHCS/OHSU J: Measuring Cortisol Levels in Persons with Parkinson's (PD)
56) An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
57) VAPORHCS/OHSU J: Efficient diagnostic tools to evaluate central auditory dysfunction
58) A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120mg Plus BSC Vs Placebo Plus BSC For Tumor Control In Subjects With Well-Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors
59) Automatic Voice-Based Assessment of Language Abilities
60) IIT: A Phase II study of Obinutuzumab (GA-101) in Combination with Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma (ML29535)
61) Prosody Assessment Toolbox
62) CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
63) Clinic Interactions of a Brain-Computer Interface for Communication
64) A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile
65) Human blood collection to support research assay development
66) Attention, Emotion, and Neurophysiology across Development
67) A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
68) Serial Measurements of Molecular and Architectural Responses to Therapy
69) A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versusPlacebo in Subjects with High Risk Invasive Urothelial Carcinoma
70) A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
71) CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
72) Clofazimine in the treatment of pulmonary Mycobacterium avium complex (MAC) disease
73) The OHSU Pancreas Community Registry
74) Knight Cardiovascular Institute Aortic Disease Registry
75) (ONC-DPX-Survivac-06): A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer
76) INTense Exercise foR surVivAL among men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-MCRPC): A Multicenter, Randomized, Controlled, Phase III Study
77) Internet-based Conversational Engagement Clinical Trial
78) A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
79) Feasibility of Medical Abortion by direct-to-consumer telemedicine
80) [NCI CIRB] The National Myelodysplastic Syndromes (MDS) Study
81) A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
82) A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC-402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
83) A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma
84) Response Assessment to Pembrolizumab with Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging– A Pilot Study
85) Molecular Mechanisms of Tumor Evolution and Resistance to Therapy
86) VAPORHCS/OHSU J: The brain-behavior relationship: age, hearing, and their effects on understanding speech in noise
87) A Phase 1 Non-Randomized, Open-Label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies
88) Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta
89) A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN)
90) Improving the effectiveness of orally-dosed emergency contraceptives in obese women
91) [Advarra – IAA] CINC280A2201: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
92) A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
93) VAPORHCS/OHSU J: The use of repetitive transmagnetic stimulation to target craving in methamphetamine use disorder (MIRB 3856)
94) AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH)
95) A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
96) A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
97) A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
98) Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia
99) Phase 1b/2 Study of BI 836858 with Azacitidine in Previously Untreate AML Patients >60 Years With Unique Molecular Features
100) A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
101) Substance-Induced Changes in Neurocircuitry in 21 year olds
102) A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
103) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
104) Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
105) A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced Solid Tumors
106) The use of perfusion MRI using ferumoxytol and small molecular weight gadolinium (Gd) agents to assess response to pembrolizumab in brain metastases and systemic lesions in NSCLC: A comparison of imaging modalities to address brain metastases, pseudoprogression and systemic lesion tumor flare (neuro-check pilot)
107) (TESARO 4010-01-001) A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
108) Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate with Prednisone and Androgen Deprivation Therapy after Treatment with Docetaxel and Androgen Deprivation Therapy
109) [NCI CIRB] A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
110) A Phase 1B Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
111) A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy
112) A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
113) Wide-field and Projection-Resolved Optical Coherence Tomography Angiography in Diabetic Retinopathy
114) Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
115) A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy
116) A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with MLL gene rearrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)
117) A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
118) A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
119) A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Relapsed/Refractory Myelodysplastic Syndromes
120) A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED ≥6 MONTHS TO
121) IIT Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma
122) A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
123) A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
124) DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study
125) [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
126) VAPORHCS/OHSU J: Brain Training For Central Auditory Dysfunction After Traumatic Brain Injury
127) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
128) A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients with Advanced Malignancies
129) A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
130) VAPORHCS/OHSU J: Evaluation of a Spasticity Management Program for People with Multiple Sclerosis
131) Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study
132) An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of Vilaprisan in subjects with uterine fibroids versus standard of care
133) VHAPORHCS/OHSU J: STAT-PD: Preventing Levodopa Induced Dyskinesia in Parkinson's disease with HMG-CoA Reductase Inhibitors (MIRB # 3869)
134) VAPORHCS/OHSU J:Neurobiology of Alcohol and Nicotine Co-Addiction
135) VAPORHCS/OHSU J:Rehabilitation of Complex TBI with Sensory Integration Balance Deficits; Can Early Initiation of Rehabilitation with Wearable Sensor Technology Improve Outcomes?
136) Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome
137) VAPORHCS/OHSU J:Photosensitivity and Pain in Complex Traumatic Brain Injury
138) A Phase 3, Multi-Center, Open-Label Randomized Study of Oral Asciminib Versus Bosutinib in Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or more Tyrosine Kinase Inhibitors
139) The effect of intervention for vocal fold immobility (VFI) on cough effectiveness
140) [NCI CIRB] A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
141) MonarchE: Protocol 13Y-MC-JPCF A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
142) A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
143) A Phase 2 Study of Entospletinib and Decitabine Targeting Mutant TP53 and or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia > Age 60 years
144) A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age > 60 years
145) A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial
146) A Phase 1/1b/2a, 3-Part, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination with Venetoclax in Subjects with Relapsed or Refractory Hematologic Malignancies
147) A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
148) A Phase 2 open-label study of the CSF1R inhibitor JNJ-40346527 in patients with relapsed/refractory acute myeloid leukemia (AML)
149) [Utah-IREx] Characterizing Uveitis by Gene Expression
150) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
151) A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
152) VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
153) CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
154) VAPORHCS/OHSU J: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
155) Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer
156) A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
157) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma
158) TRITON3: A Multicenter, Randomized, Open-Label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency (protocol CO-338-063)
159) A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
160) Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage’s CIVO™ device in soft tissue sarcoma patients undergoing surgery.
161) Natural History Study of CEP290-Related Retinal Degeneration
162) A pharmacokinetic study of Centella asiatica product (CAP) in elderly participants with mild cognitive impairment receiving cholinesterase inhibitor therapy
163) Exercising Together: A randomized controlled trial of partnered exercise training on the health of couples coping with cancer
164) Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
165) Effect of tetrahydrocannabinol (THC) on sleep in humans
166) A Phase I/II, open-label, multi-center study evaluating the safety and efficacy of Ruxolitinib and CPX-351 in combination for the treatment of Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms.
167) [JAEB IRB] Myopia Treatment Study 1
168) [NCI CIRB] S1609, "DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS”
169) Phase 2 Study with Pevonedistat in combination with Azacitidine targeting NEDD8-activating enzyme (NAE) in TP53 Mutant Untreated Acute Myeloid Leukemia patients ≥ 60 years of age
170) Modular phase 2 study to link combination immune-therapy to patients with advanced solid and hematologic malignancies Module 9: PDR001 plus LAG525 for patients with advanced solid and hematologic malignancies
171) A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma
172) A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
173) A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy
174) [WIRB – MOU ADRN] Effect of Dupilumab (anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
175) VAPORHCS/OHSU J: Brain Function and Connectivity in Methamphetamine Dependence: The Link to Neuroinflammation and the Effects of Ibudilast
176) Peptide Biomarkers for Alzheimer Disease
177) Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
178) Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
179) An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
180) A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies
181) Teen Musculoskeletal Pain Outcomes (TEMPO)
182) A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at High Risk for CVD
183) [NCI CIRB] A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
184) A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
185) A novel therapeutic intervention to restore health and functioning in persons with chemotherapy-induced peripheral neuropathy
186) A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
187) Group Exercise Training for Fall Prevention and Functional Improvements During and After Treatment for Prostate Cancer
188) An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
189) Monoclonal antibody-based sequential therapy for deep remission in multiple myeloma – MASTER trial
190) [NCI CIRB] S1702, A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
191) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
192) [Washington University IRB - SMART IRB] Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy
193) An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
194) Phase 2 Study of AG-120 combined with Azacitidine in Previously Untreated AML Patients > 60 Years with an IDH1 Mutation
195) A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible, Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)
196) MODERATE – Monitoring dementia-related agitation using technology evaluation
197) A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 IN PATIENTS WITH ADVANCED SOLID TUMORS
198) VAPORHCS/OHSU J: Validation of Walking Aid Use Metrics in People with Multiple Sclerosis Using an Innovative, New Device: HoldTrak
199) A Phase II, Open Label, Study of Olaparib and Durvalumab in Patients with Metastatic Triple Negative Breast Cancer
200) [WIRB - IAA] Gilteritinib Monotherapy or in Combination with Decitabine in Elderly Untreated FLT3 mutated Acute Myeloid Leukemia With High and Low Variant Allele Frequency (VAF)
201) A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
202) Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System
203) A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination with PD-1 Antagonist Nivolumab in Patients with Transformed Chronic Lymphocytic Leukemia (Richter’s Transformation) or Non-Hodgkin Lymphoma
204) A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) or chemotherapy plus placebo in newly diagnosed patients with FLT-3 mutation negative acute myeloid leukemia (AML)
205) A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
206) Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin (Mylotarg) in Combination with Cytarabine, Anthracycline and Midostaurin Induction for Patients with Newly Diagnosed FLT3 Positive Acute Myeloid Leukemia (AML)
207) Neuro-correlates of motor fatigue in MS
208) [Advarra-IAA] A Randomized, double-blind, placebo controlled study to evaluate efficacy and safety of nefecon in patients with primary IgA nephropathy at risk of progressing to End-Stage renal disease (NefIgArd)
209) A Phase 3, Randomized, Double-blind, Active Comparator controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)
210) MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
211) The Impact of Pediatric Skin Disorders: The "Big" Study.
212) Validating a Cell Culture for studying cervical mucus and measuring copper levels in mucus.
213) A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies
214) Comparison of two- versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease
215) A phase 1 study of FOR46 administered every 21 days in patients with metastatic castration-resistant prostate cancer (mCRPC)
216) A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
217) A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA
218) Transcatheter Aortic Valve Replacement (TAVR) with Medtronic TAVR System in Patients with Severe Bicuspid Aortic Valve Stenosis and at Low Predicted Risk of Mortality with Surgical Aortic Valve Replacement (SAVR)
219) A Phase II study of Xisomab 3G3, a monoclonal antibody preventing the activation of FXI by FXIIa, for the prophylaxis of PICC line-associated thrombosis.
220) Mechanisms of Action of MBCT-PD: A Pilot Study
221) A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
222) [Advarra IAA]- A phase 3, multi-center, open-label study of a levonorgestrel 52 MG intrauterine system for the treatment of heavy menstrual bleeding
223) VAPORHC/OHSUJ: Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis
224) VAPORHCS/OHSU J: HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
225) [NCI CIRB] EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
226) [NCI CIRB] S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
227) A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
228) STUDY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB AS MAINTENANCE TREATMENT FOR PATIENTS WITH LIMITED STAGE SMALL-CELL LUNG CANCER WHO HAVE NOT PROGRESSED FOLLOWING CONCURRENT CHEMORADIATION THERAPY (ADRIATIC)
229) [NCI CIRB] NRG-BN003: A Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
230) SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
231) An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post– ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
232) A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
233) A Targeted approach to examine the influence of maternal psychological stress on newborn brain outcomes
234) [WIRB – MOU ADRN] ADRN-06 Integrated Extreme Trait Analysis to Understand the Etiology of Eczema Herpeticum Etiology of EH
235) The effect of a sub-symptom threshold aerobic exercise program on recovery in concussed athletes
236) A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED TRIAL OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE FOR HER2LOW, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS
237) A Window of Opportunity Strategy for Targeted PARP or MEK/ERK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
238) [NCI CIRB] A041501 - A Phase III Trial To Evaluate the Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All
239) Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
240) A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
241) A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors
242) A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
243) A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
244) A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
245) A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
246) A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer
247) Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
248) The STELLA Collaborative:Using Technology to Advance ADRD Family Education and Support
249) A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
250) Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial fibrillation (ARTESiA)
251) [MCW IRB-CML MOU] Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients who Relapsed After a Prior Attempt at TKI Discontinuation
252) A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
253) Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML)
254) An open label pilot trial of guselkumab in the treatment of adults with Pityriasis Rubra Pilaris (PRP)
255) Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)
256) A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III)
257) A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects with Hematological Malignancies
258) Aging Well with Independence using Sensors in the Environment
259) An open-label, multi-institutional phase 0 study to assess the use of glucarpidase in patients with osteosarcoma receiving high-dose methotrexate
260) A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
261) A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
262) Electronic Financial Indicators of Neurodegenerative Disease
263) A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
264) SPYRAL HTN-ON MED
265) VAPORHCS/OHSU J: Improving sleep, sleep-related outcomes, and biomarkers in Veterans
266) Evaluation of the effect of RNS60 on mitochondrial oxidative metabolism and potential pharmacodynamics markers.
267) PHASE 2 ACTIVE TREATMENT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SRK-015 IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (TOPAZ)
268) [NCI CIRB] LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
269) Differentiating High Myopia from Glaucoma Using Functional and Structural Optical Coherence Tomography
270) A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
271) [Quorum Review - SMART IRB] A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure
272) A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
273) [NCI CIRB] S1900A - A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRAC1/2 Mutation Stage IV or Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub Study)
274) A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
275) A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT® FOR ATOPIC DERMATITIS (R668-AD-1762)
276) An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K δ/γ dual inhibitor, given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma
277) Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (triFluridine/tIpiracil) with ConcurrEnt Radiation in Previously Untreated Resectable Stage II and Stage III ReCtal CancEr (FIERCE)
278) A Phase 3, Randomized Study of Zanubrutinib (BGB 3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
279) [Advarra - SMART IRB] A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD˗9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
280) Randomized, Open-label, Active-controlled Study to Assess the Safety, Tolerability and Efficacy of Afabicin IV/oral in the Treatment of Patients with Bone or Joint Infection due to Staphylococcus
281) A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
282) [NCI CIRB] S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
283) [NCI CIRB] EA8143 (PROSPER): A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
284) An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis
285) A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
286) A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies
287) ADJUVANT THERAPY WITH PEMBROLIZUMAB VERSUS PLACEBO IN RESECTED HIGHRISK STAGE II MELANOMA: A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY (KEYNOTE 716)
288) A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
289) [Prime-Smart IRB] A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety of TOL-3021 in Patients with New Onset or Established Type 1 Diabetes Mellitus
290) [NCI CIRB] EA9161 - A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
291) An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer
292) A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
293) A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
294) [NMDP - BMT CTN MOU] A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
295) [WIRB - IAA] A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
296) A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)
297) A Phase 3 Randomized, Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza infection in Immunocompromised Subjects
298) [NCI CIRB] - A041702 - A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (≥ 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
299) [NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
300) [WIRB - IAA] WATCH-PD (Wearable Assessments in the Clinic and Home in PD)
301) A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC- 10004) IN SUBJECTS WITH MODERATE TO SEVERE GENITAL PSORIASIS
302) [Advarra IRB - SMART IRB] A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects with Active Nonradiographic Axial Spondyloarthritis.
303) A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
304) A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
305) A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF EQ001 IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE GRAFT VERSUS HOST DISEASE
306) [Advarra IRB- IAA] A Phase 3 multicenter, randomized, double-blind, placebo controlled,clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain.
307) [NMDP - BMT CTN MOU] 1702: Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)
308) [VUMC - IREx] The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea (LOFT-HF)
309) A Phase 1, Multicenter, Open-Label, Dose Finding Study of CC 99712, A BCMA Antibody-Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma
310) [NMDP - BMT CTN MOU] CTN 1704: Composite Health Assessment Model for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation (CHARM)
311) A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA
312) Early detection of hereditary transthyretin amyloid polyneuropathy using in-vivo reflectance confocal microscopy of Meissner's corpuscles
313) [NCI CIRB] A031704 - PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
314) [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
315) [NCI CIRB] - EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
316) Delivering Enhanced Milieu Teaching Via Telehealth to Children and Families in Rural Communities
317) Early Access Program (EAP) for avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
318) Comparison of GI transit times in levodopa-responders and non-responders in patients with Parkinson's disease
319) A Randomized Controlled Trial to Assess the Effectiveness of Virtual Reality in Education for Cancer Patients Undergoing Radiation Therapy
320) A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.
321) A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients
322) [NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
323) [NCI CIRB] S1800A - A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care For Patients Previously Treated With Immunotherapy For Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Non-Matched Sub-Study)
324) A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
325) Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
326) A phase 3, multi-center, randomized, open-label, assessor-blind stay to evaluate the efficacy and safety of Mino-Lok Therapy (MLT) in combination with systemic antibiotics in the treatment of catheter-related or central line-associated bloodstream infection.
327) Evaluating the effects of resistance and aerobic exercise on glucose and lipids in pregnant women with gestational diabetes
328) A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
329) Using Optical Coherence Tomography Angiography to Capture Dynamic Retinal Vascular Changes in Demyelinating Disease
330) VAPORHCS/OHSU J: A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People with MS
331) (BCH IRB) Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia (TransIT)
332) A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis, BEAT-MS
333) [NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
334) [NCI CIRB] S1803: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION (DRAMMATIC STUDY)
335) ORCASTRAIT Oregon Roybal Center for CAre Support Translational Research Advantaged by Integrating Technology
336) A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
337) An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
338) [IntegReview IRB - IAA] A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
339) VAPORHCS/OHSU J: MitoQ for fatigue in multiple sclerosis: a placebo controlled trial
340) Cerebellar transcranial magnetic stimulation for motor control in progressive supranuclear palsy
341) [NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
342) Clinical Effectiveness of Conventional Versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MIPLATE)
343) Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
344) Assessing Cardiovascular Health Risk in Grandfamilies
345) A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
346) A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION
347) Diet, Microbiome and Interval Breast Cancer Study
348) Sedentary Behavior, Cardiovascular Function, and Sleep
349) [NCI CIRB] S1826 - A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
350) A Randomized Trial of Standard Verbal Counseling with or without a Pictorial Educational Tool to Reduce Psychological Morbidity in Women Receiving Breast Radiation Therapy
351) A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
352) CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY
353) A Phase 1b trial of CPX-351 Lower Intensity Therapy (LIT) plus Venetoclax as First Line Treatment for Subjects with AML who are Unfit for Intensive Chemotherapy
354) Disparities and Barriers to Care for Gender Non-conforming Patients with Epilepsy and Spells: A longitudinal study - PSU MOU- Build Exito
355) DCC-2618-99-001: Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies
356) A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
357) Development of a Machine Learning Model for Prostate Cancer Treatment Planning
358) Yoga-Pilates Exercise & the Effects on Urethral Rhabdosphincter Morphology and Stress Urinary Incontinence
359) [NCI CIRB] EA4181 - A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients
360) Characteristics Associated with Communicative Participation after Total Laryngectomy
361) A Multicenter Phase Ib Trial for Patients with Advanced Hematologic Malignancies undergoing Allogeneic Hematopoietic Cell Transplantation with TregGraft, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells
362) MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
363) A Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma
364) [WIRB - IAA] A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
365) A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis
366) Cannabidiol and Oral Contraceptive Pills: Exploring a Substance-Drug Interaction
367) [NCI CIRB] A051701 - Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
368) [Advarra - IAA] - TRC-PAD Program: In-Clinic Trial-Ready Cohort for the Prevention of Alzheimer's Disease - Protocol ATRI-004
369) A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma - Expansion Cohort Segment Only
370) A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
371) An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
372) Phase II randomized multi-center trial of total neoadjuvant therapy with and without CD40 agonist, APX005M, for locally advanced rectal adenocarcinoma
373) [WIRB- IAA] Phase 1b/2 Study of AZD5153 Combined with Venetoclax in Relapsed/Refractory (Phase 1b) and Previously Untreated AML Patients (Phase 2)
374) [WIRB- IAA] Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥ Age 60 years
375) [Advarra-IAA] Clinical Evaluation of Daily Application Nestorone® (NES) and Testosterone (T) Combination Gel for Male contraception
376) Understanding the Experience of Adolescent and Young Adult Cancer (AYA Cancer Study)
377) EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE
Return to Search